HOLLISTON, Mass. -- (Business Wire)
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a
clinical stage biotechnology company developing regenerated organs for
transplant, initially focused on the trachea, will hold a conference
call to discuss recent events at 11:00 AM (Eastern Time) on December 23,
2014. On that call, management may take questions from the audience on
any of a number of topics related to the business, including operations,
plans and outlook.
Investors can access the live conference call by dialing the following
phone numbers: toll-free 888-466-4462, or toll/international:
719-325-2308, and referencing the pass code “3088315”.
If you are unable to listen to the live conference call, a replay will
be available from approximately 2:00 PM (Eastern Time) on December 23,
2014 through 2:00 PM (Eastern Time) on December 30, 2014 and will be
accessible by dialing toll-free 888-203-1112, or toll/international
719-457-0820, and referencing the pass code “3088315”. The replay will
also be made available on the company’s web site, www.hartregen.com.
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology makes regenerated organs for
transplant. Our first product, the HART-Trachea, is intended to replace
or repair a trachea that has been severely damaged by either trachea
cancer or physical trauma. Our HART-Trachea technology has been used in
six human trachea transplants to date approved under compassionate use
exemptions, but none of our products are yet approved by a government
regulatory authority for marketing. On November 1, 2013, HART was
spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is
used under a sublicense agreement with Harvard Bioscience, who has
licensed the right to use such trademark from Harvard University.
Contacts:
Harvard Apparatus Regenerative Technology, Inc.:
David Green,
774-233-7320
President and CEO
dgreen@HARTregen.com
or
Tom
McNaughton, 774-233-7321
CFO
tmcnaughton@HARTregen.com
Source: Harvard Apparatus Regenerative Technology, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.